Calidi Biotherapeutics, Inc.
CLDI · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -90% | – |
| Cost of Goods Sold | $0 | $1 | $0 | $0 |
| Gross Profit | $0 | -$1 | -$0 | $0 |
| % Margin | – | – | -508.9% | 79.1% |
| R&D Expenses | $9 | $13 | $7 | $5 |
| G&A Expenses | $13 | $16 | $16 | $6 |
| SG&A Expenses | $13 | $16 | $16 | $6 |
| Sales & Mktg Exp. | $0 | $0 | -$0 | $0 |
| Other Operating Expenses | $0 | -$1 | $0 | $0 |
| Operating Expenses | $22 | $28 | $23 | $11 |
| Operating Income | -$22 | -$29 | -$23 | -$10 |
| % Margin | – | – | -51,395.6% | -2,334.5% |
| Other Income/Exp. Net | -$0 | -$0 | -$2 | $14 |
| Pre-Tax Income | -$22 | -$29 | -$25 | $3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$22 | -$29 | -$25 | -$11 |
| % Margin | – | – | -56,504.4% | -2,435% |
| EPS | -35.7 | -207.61 | -358.8 | 14.16 |
| % Growth | 82.8% | 42.1% | -2,633.9% | – |
| EPS Diluted | -35.7 | -207.61 | -358.8 | 14.16 |
| Weighted Avg Shares Out | 1 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $4 | $0 | $1 |
| Depreciation & Amortization | $2 | $1 | $0 | $0 |
| EBITDA | -$20 | -$24 | -$25 | -$9 |
| % Margin | – | – | -55,551.1% | -2,104.7% |